Evidence map›Paper›PMID 41440898›Full record

ArticleMarine drugs2025

Mechanistic Investigation of Adociaquinone and Xestoquinone Derivatives in Breast Cancer Cells.

Yu-Dong Zhou, Fakhri Mahdi, Nicholas M Nagle, Mika B Jekabsons, Dale G Nagle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu-Dong ZhouNational Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, MS 38677-1848, USA.ORCID 0000-0002-3090-9202
Fakhri MahdiDepartment of Biomolecular Sciences, School of Pharmacy, University of Mississippi, Oxford, MS 38677-1848, USA.ORCID 0000-0003-4891-2992
Nicholas M NagleSchool of Engineering, University of Mississippi, Oxford, MS 38677-1848, USA.
Mika B JekabsonsDepartment of Biology, College of Liberal Arts, University of Mississippi, Oxford, MS 38677-1848, USA.ORCID 0000-0002-4013-5095
Dale G NagleDepartment of Biomolecular Sciences, School of Pharmacy, University of Mississippi, Oxford, MS 38677-1848, USA.ORCID 0000-0001-7883-2673

Funding

ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIAR01CA098787 · NCI · UNIVERSITY OF MISSISSIPPI · PI NAGLE, DALE G · 2004 to 2013
$2.4M
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIAR56CA098787 · NCI · UNIVERSITY OF MISSISSIPPI · PI NAGLE, DALE G · 2008 to 2008
$264k
Ergon Cancer Research Endowment NCNPR/UMNCI NIH HHS R01 CA098787NCI NIH HHS R56 CA098787NIH HHS 1R01CA098787-10
6 · The paper itself

Abstract

Xestoquinone derivatives isolated from marine sponges exhibit a range of bioactivities, including the inhibition of HIF signaling, mitochondrial function, and tumor cell proliferation. Mechanistic investigation suggested that 14-hydroxymethylxestoquinone (

Indexed as

Antineoplastic AgentsBreast NeoplasmsPoriferaQuinonesAnimalsCell Line, TumorCell ProliferationFemaleHumansMembrane Potential, MitochondrialOxygen ConsumptionSignal TransductionAntineoplastic AgentsQuinonesadociaquinonebreast cancer cellsHIF-1mechanism of actionredox cyclingrespirationstress responsexestoquinone

Identifiers

PMID41440898
PMCPMC12734807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.